Institute of Cancer Research, London

The Institute of Cancer Research (ICR), based in London, is a global leader in cancer research. It is a charitable trust and a university, dedicated to understanding cancer and developing new treatments. The ICR is currently in the news due to its significant contributions to groundbreaking cancer therapies. Recent developments highlighted in news articles include the success of immunotherapy drugs like durvalumab in treating bladder cancer, potentially sparing patients from life-altering surgery. Furthermore, the ICR is involved in trials of innovative treatments such as amivantamab, a triple-action cancer jab showing unprecedented results in eradicating entire tumors in patients with advanced or recurrent cancers. These advancements underscore the ICR's vital role in pushing the boundaries of cancer treatment and improving patient outcomes worldwide.